Cadence Gets Option to Buy Incline

6/21/10Follow @xconomy

Cadence Pharmaceuticals (NASDAQ: CADX), the San Diego-based developer of an intravenous form of acetaminophen for pain relief in hospitals, said today it has obtained an exclusive option to acquire Redwood City, CA-based Incline Therapeutics. Separately, Incline announced it has raised $43 million in Series A venture financing to develop its fentanyl iontophoretic transdermal system (Ionsys), a pain reliever patients can give to themselves following surgery. Cadence also announced it has secured a $30 million debt financing from Oxford Finance, Silicon Valley Bank, and GE Financial Services.

By posting a comment, you agree to our terms and conditions.